CD274 and non-small cell lung carcinoma: A total of 572 stage IV NSCLC patients with PD-L1 ≥ 1% were randomized to atezolizumab, a PD-L1 inhibitor, at 1200 mg every three weeks, versus platinum-based chemotherapy.